Last reviewed · How we verify
Ethosomal gel bearing losartan 5% — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ethosomal gel bearing losartan 5% (Ethosomal gel bearing losartan 5%) — Yuni Eka Anggraini.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ethosomal gel bearing losartan 5% TARGET | Ethosomal gel bearing losartan 5% | Yuni Eka Anggraini | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ethosomal gel bearing losartan 5% CI watch — RSS
- Ethosomal gel bearing losartan 5% CI watch — Atom
- Ethosomal gel bearing losartan 5% CI watch — JSON
- Ethosomal gel bearing losartan 5% alone — RSS
Cite this brief
Drug Landscape (2026). Ethosomal gel bearing losartan 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/ethosomal-gel-bearing-losartan-5. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab